Security
Galmed Pharmaceuticals Ltd. Ordinary Shares · GLMD
GLMDNASDAQCommon stockHistorical · closed Sep 9, 2026CIK 1595353Updated Oct 6, 2026
Current security for this SEC filerEOCN · NASDAQ
GLMD price & chart
Historical security
This listing closed Sep 9, 2026. Live provider charts are shown only for current listings.
Current security: EOCN
In the news
Galmed Issues CEO Letter to Shareholders News provided by Galmed Pharmaceuticals Ltd. Dec 01, 2025, 08:30 ET Share this article Share to X Share this article Share to X TEL AVIV, Israel , Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed" or the "Company"), a clinical ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 21,584,000Source | — | 22,944,000Source | 13,341,000Source | 13,277,000Source | 23,575,000Source | 52,325,000Source | 64,849,000Source | 18,627,000Source | 18,500,000Source | 16,629,000Source | 16,561,000Source |
| Property, Plant and EquipmentUSD | — | — | — | — | 97,000Source | 130,000Source | 163,000Source | 157,000Source | — | — | 83,000Source | 114,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 3,314,000Source | — | 4,964,000Source | 1,837,000Source | 1,009,000Source | 1,980,000Source | 7,923,000Source | 5,553,000Source | 3,985,000Source | 4,652,000Source | 2,861,000Source | 2,016,000Source |
| Assets, CurrentUSD | 19,724,000Source | — | 21,084,000Source | 10,076,000Source | 9,786,000Source | 23,130,000Source | 51,665,000Source | 64,211,000Source | 18,627,000Source | 16,124,000Source | 13,239,000Source | 14,724,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | 267,000Source | — | — | — |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | 129,000Source | 315,000Source | 497,000Source | 481,000Source | — | — | 42,000Source | 223,000Source |
| Other Assets, NoncurrentUSD | 267,000Source | — | 267,000Source | — | — | — | — | — | — | 257,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 2,786,000Source | — | 2,690,000Source | 263,000Source | 70,000Source | 70,000Source | 70,000Source | 58,000Source | 3,408,000Source | 742,000Source | 209,000Source | 70,000Source |
| Additional Paid in CapitalUSD | 222,602,000Source | — | 222,304,000Source | 207,305,000Source | 200,609,000Source | 199,675,000Source | 197,829,000Source | 177,853,000Source | 223,455,000Source | 216,470,000Source | 207,076,000Source | 200,138,000Source |
| Retained Earnings (Accumulated Deficit)USD | -205,960,000Source | — | -204,068,000Source | -195,346,000Source | -189,463,000Source | -178,051,000Source | -153,008,000Source | -118,525,000Source | -210,778,000Source | -200,469,000Source | -192,952,000Source | -186,040,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -316,000Source | — | -403,000Source | -435,000Source | -662,000Source | -982,000Source | 108,000Source | 498,000Source | -303,000Source | -416,000Source | -454,000Source | -745,000Source |
| Stockholders' Equity Attributable to ParentUSD | 19,112,000Source | 18,436,000Source | 20,523,000Source | 11,787,000Source | 10,554,000Source | 20,712,000Source | 44,999,000Source | 59,884,000Source | 15,782,000Source | 16,327,000Source | 13,879,000Source | 13,423,000Source |
| Liabilities and EquityUSD | 21,584,000Source | — | 22,944,000Source | 13,341,000Source | 13,277,000Source | 23,575,000Source | 52,325,000Source | 64,849,000Source | 18,627,000Source | 18,500,000Source | 16,629,000Source | 16,561,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,472,000Source | — | 2,421,000Source | 1,554,000Source | 2,723,000Source | 2,729,000Source | 7,008,000Source | 4,714,000Source | 2,845,000Source | 2,173,000Source | 2,750,000Source | 3,094,000Source |
| Accounts Payable, CurrentUSD | 1,674,000Source | — | 1,369,000Source | 1,203,000Source | 2,140,000Source | 2,089,000Source | 5,629,000Source | — | 2,003,000Source | 1,308,000Source | 1,879,000Source | 2,560,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | 134,000Source | 318,000Source | 251,000Source | — | — | — | 44,000Source |
| Additional Financial Items | ||||||||||||
| Short-term InvestmentsUSD | — | — | — | — | 7,600,000Source | 20,400,000Source | — | 27,406,000Source | 7,000,000Source | 7,200,000Source | 7,500,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | 6,900,000Source | 8,000,000Source | 6,900,000Source | -17,900,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortizationUSD | — | — | — | — | — | — | — | — | — | 83,000Source | 31,000Source | 35,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | 546,000Source | 531,000Source | 892,000Source | 1,296,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | — | -6,315,000Source | -5,880,000Source | -6,137,000Source | -18,501,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -3,375,000Source | -1,111,000Source | 800,000Source | 17,563,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 4,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 9,026,000Source | 8,786,000Source | 6,185,000Source | 70,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | -664,000Source | 1,795,000Source | 848,000Source | -868,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 914,000Source | 503,000Source | 376,000Source | 297,000Source |
| Additional Financial Items | ||||||||||||
| DepreciationUSD | — | — | — | — | — | — | — | — | — | 80,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | 76,000Source | -40,000Source | 36,000Source | -36,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | -81,000Source | -12,000Source | -13,000Source | — |
| General and Administrative ExpenseUSD | — | — | 1,009,000Source | 1,273,000Source | 1,051,000Source | 688,000Source | 1,062,000Source | 1,150,000Source | 3,636,000Source | 3,299,000Source | 3,923,000Source | 4,656,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | 7,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,892,000Source | -1,914,000Source | -2,495,000Source | -1,119,000Source | -1,593,000Source | -3,734,000Source | -10,309,000Source | -7,517,000Source | -6,912,000Source | -17,866,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -741,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 2,095,000Source | 2,011,000Source | 2,109,000Source | 1,222,000Source | 1,871,000Source | 3,730,000Source | 8,510,000Source | 6,278,000Source | 7,492,000Source | 17,651,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 40,000Source | 200,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 203,000Source | 97,000Source | 140,000Source | 103,000Source | 278,000Source | -4,000Source | 741,000Source | 516,000Source | 580,000Source | -215,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | — | — | 6,000,000Source | 6,000,000Source | 60,000,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 7,670,000Source | 4,386,000Source | — | — |
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Nonoperating Income (Expense)USD | — | — | 203,000Source | 97,000Source | 140,000Source | 103,000Source | 278,000Source | -4,000Source | 741,000Source | 516,000Source | 580,000Source | -215,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | 7,517,000Source | -6,912,000Source | -17,866,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,892,000Source | -1,914,000Source | -2,495,000Source | -1,119,000Source | -1,593,000Source | -3,734,000Source | -10,309,000Source | -7,517,000Source | -6,912,000Source | -17,866,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.33Source | 2.31Source | 0.63Source | 1.65Source | 0.95Source | 2.25Source | 2.39Source | 8.08Source | 2.5Source | 0.71Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.33Source | 2.31Source | 0.63Source | 1.65Source | 0.95Source | 2.25Source | 2.39Source | 8.08Source | 2.5Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 5,460,476Source | 829,500Source | 3,948,190Source | 677,861Source | 1,680,232Source | 1,672,561Source | 4,311,323Source | 930,822Source | 2,769,539Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 5,460,476Source | 829,500Source | 3,948,190Source | 677,861Source | 1,680,232Source | 1,672,561Source | 4,311,323Source | 930,822Source | 2,769,539Source | 25,142,741Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 83,000Source | 31,000Source | 35,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | 76,000Source | -40,000Source | 36,000Source | -36,000Source |
| General and Administrative ExpenseUSD | — | — | 1,009,000Source | 1,273,000Source | 1,051,000Source | 688,000Source | 1,062,000Source | 1,150,000Source | 3,636,000Source | 3,299,000Source | 3,923,000Source | 4,656,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | 7,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | -741,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 2,095,000Source | 2,011,000Source | 2,109,000Source | 1,222,000Source | 1,871,000Source | 3,730,000Source | 8,510,000Source | 6,278,000Source | 7,492,000Source | 17,651,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | 40,000Source | 200,000Source | — |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | — | 100,000Source | — |
| Research and Development ExpenseUSD | — | — | 1,086,000Source | 738,000Source | 1,058,000Source | 534,000Source | 809,000Source | 2,580,000Source | 4,874,000Source | 2,979,000Source | 3,569,000Source | 12,995,000Source |
| Debt Securities, Gain (Loss) | — | — | — | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-289703
Filing attachments
ex99-1.htm · 6-K · 2026-09-09
Exhibit 99.1 Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol “EOCN” to Reflect its New Dawn Platform for GI Innovation Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) will be terminated effective immediately The Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and will continue to be listed and traded on the Nasdaq Capital Market under the new ticker symbol RAMAT-GAN, Israel, Se…
Read attachment ↗ex99-2.htm · 6-K · 2026-09-09
Exhibit 99.2 THE COMPANIES LAW, 5759-1999 AMENDED AND RESTATED ARTICLES OF ASSOCIATION of EOCENE LTD איוסין בע”מ Preliminary (a) In these Articles, unless the context otherwise requires: (a) An “Annual General Meeting” shall have the meaning ascribed to such term in Article 50 hereunder. (b) The “Board of Directors” or “Board” means the board of directors of the Company. (c) A “Board Meeting” means a meeting of the Board of Dir…
Read attachment ↗ex99-1.htm · 6-K/A · 2026-08-19
Exhibit 99.1 GALMED PHARMACEUTICALS LTD. August 19, 2026 c/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Dear Shareholder: You are cordially invited to attend the Annual General Meeting of Shareholders of Galmed Pharmaceuticals Ltd. (the “ Company ”) to be held at 4:00 p.m., Israel time, on Wednesday, September 2, 2026, at the registered offices of Meitar | Law Offices, legal counsel to the Company, at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel (the “ Meetin…
Read attachment ↗ex99-2.htm · 6-K/A · 2026-08-19
Exhibit 99.2 EACH SHAREHOLDER IS URGED TO COMPLETE, DATE, SIGN AND PROMPTLY RETURN THE ENCLOSED PROXY Annual General Meeting of Shareholders of GALMED PHARMACEUTICALS LTD. September 2, 2026 NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL: The amended notice of the meeting, amended proxy statement and amended proxy card are available at http://galmedpharma.investorroom.com/ THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints each…
Read attachment ↗ex99-1.htm · 6-K · 2026-08-19
Exhibit 99.1 Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan’s Novel Intraoperative Tissue Assessment Technology The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality. The study establishes the clinical foundation for novel intraoperative tissue assessm…
Read attachment ↗ex99-1.htm · 6-K · 2026-08-17
Exhibit 99.1 Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global …
Read attachment ↗